Qumis | $2,200,000 | (Jan 22, 2025)
ExSURE PVT. LTD. | $347,401 | (Jan 22, 2025)
Belfry | $12,000,000 | (Jan 22, 2025)
AVS Pulse
United States
- Ann Arbor, Michigan
- 05/04/2023
- Series B
- $8,800,000
AVS is an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2018 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer at AVS. We are redefining interventional therapy for severely calcified lesions with our Pulse IVL System, which uses a novel pulsatile mechanism of action to shatter calcium and expand narrowed vessels, all with a single device. To learn more about pulsatile intravascular lithotripsy, visit www.avspulse.com.
- Industry Medical Equipment Manufacturing
- Website https://www.avspulse.com/
- LinkedIn https://www.linkedin.com/company/avspulse/
Related People
Robert ChisenaCo Founder
United States -
Northport, New York
My passion lies in studying problems and issues in contemporary health care and developing solutions to mitigate or eliminate those problems.
Gravity(US) | $13,000,000 | (Jan 22, 2025)
LeapXpert | $20,000,000 | (Jan 22, 2025)
BPR Hub | $2,600,000 | (Jan 22, 2025)
NovoLINC | Undisclosed Amount | (Jan 22, 2025)
Percipio Health | $20,000,000 | (Jan 22, 2025)
Zynap | $5,937,902 | (Jan 22, 2025)
Highnote | $90,000,000 | (Jan 22, 2025)
IntusCare | $11,500,000 | (Jan 21, 2025)
ecoplanet | $16,571,680 | (Jan 21, 2025)